In a nutshell This study evaluated the effectiveness and safety of three different ALK tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC). The authors concluded that these inhibitors were similarly effective, but elderly patients over age 65 were more likely to develop side effects. Some background NSCLC is...
Read MoreType of lung cancer-Non-small cell lung carcinoma (NSCLC) Posts on Medivizor
Looking for patients with advanced non-small cell lung cancer to test a biological therapy.
In a nutshell This trial is examining the effectiveness of pegilodecakin (AM0010) when it is used with pembrolizumab (Keytruda) to treat patients with advanced non-small cell lung cancer (NSCLC). The main outcome to be measured will be tumor responses to the treatment. This trial is recruiting in multiple locations around the United States. The...
Read MoreLong-term survival with nivolumab treatment in non-small cell lung cancer
In a nutshell This study investigated the long-term survival of patients with non-small cell lung cancer (NSCLC) treated with nivolumab (Opdivo). They found that this treatment is well tolerated and improved survival in these patients. Some background Non-small cell lung cancer (NSCLC) is the most common form of lung cancer (LC). Over...
Read MoreSearching for patients with advanced non-small cell lung cancer to test a new combination therapy
In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be the maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may not be possible. In...
Read MoreChemoradiotherapy versus radiation only – which is more effective in inoperable lung cancer?
In a nutshell This study investigated the effectiveness of radiation therapy (RT) and chemoradiotherapy (CRT) in inoperable non-small cell lung cancer (NSCLC). They found that CRT was more effective than RT alone in these patients. Some background Non-small cell lung cancer (NSCLC) is the most common form of lung cancer (LC)....
Read MoreLooking for participants with metastatic non-small cell lung cancer to test a new immunotherapy
In a nutshell This phase 1 trial is examining the effectiveness of personalized tumor antigens (PTA) in the treatment of different advanced tumors. The main outcomes to be measured will be side effects and disease control. This study is being conducted in Arizona, California, Louisiana and New Jersey, US. The details While the tumor cells are growing,...
Read MoreEvaluating long-term outcomes for stereotactic ablative body radiotherapy for early-stage non-small cell lung cancer.
In a nutshell This study wanted to find out if using stereotactic ablative body radiotherapy (SABR) improves survival in patients with early-stage non-small cell lung cancer (NSCLC). The study found that this treatment resulted in good long-term survival and had few side effects. Some background Stereotactic ablative body radiotherapy (SABR) is...
Read MoreSearching patients with relapsed or unresponsive cancer to test a new medication
In a nutshell This phase 1b/2 trial will investigate the safety of RMC-4630 and cobimetinib (Cotellic) in relapsed or unresponsive solid tumors. The main outcomes will be the number of side effects and the overall response rate. This trial is recruiting in a number of US states. The details Relapsed/refractory (R/R) cancer is a term for...
Read MoreStereotactic body radiotherapy in patients with non-small cell lung cancer that has spread
In a nutshell This study wanted to find out how well stereotactic body radiotherapy (SBRT) works in patients with non-small cell lung cancer (NSCLC) that has spread to one or two parts of the body (oligometastatic). The study found that SBRT is a good treatment option for these patients. Some background Stereotactic body radiotherapy (SBRT)...
Read MoreSearching for patients with advanced solid tumors to test a new medication
In a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced solid tumors. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details The treatment options for advanced cancer are limited. New drugs are...
Read MoreSearching for patients with previously treated non-small cell lung cancer to trial an immunotherapy combination
In a nutshell This study wanted to find out if treating recurrent non-small cell lung cancer with ramucirumab (Cyramza) and pembrolizumab (Keytruda) works better than standard care practices. The main outcome that will be measured is the overall survival rates. This study will take place in the United States. The details There are a...
Read MoreUsing blood test results to predict survival in non-small cell lung cancer
In a nutshell This study wanted to find out if certain levels of compounds in the blood could predict survival in patients with non-small cell lung cancer (NSCLC). The study found that levels of some of the compounds tested were related to how well the patients survived. Some background The levels of certain compounds in the blood are tested...
Read More
